Premium
Bioavailability of carbonyl iron: A randomized, double‐blind study
Author(s) -
Devasthali Shirish D.,
Gordeuk Victor R.,
Brittenham Gary M.,
Bravo Joanne R.,
Hughes Margaret A.,
Keating Louise J.
Publication year - 1991
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1991.tb01538.x
Subject(s) - total iron binding capacity , hemoglobin , mean corpuscular volume , ferrous , transferrin saturation , bioavailability , serum iron , carbonyl iron , iron deficiency , chemistry , anemia , reticulocyte , medicine , sulfate , biochemistry , pharmacology , organic chemistry , messenger rna , gene , electrical engineering , engineering
49 female blood donors with iron‐deficiency anemia were treated with equal doses of iron either as carbonyl iron or ferrous sulfate in a randomized, double‐blind fashion. The prevalence of side‐effects was similar in the two groups. Mean values for hemoglobin concentration, mean corpuscular volume, corrected reticulocyte count, platelet count, serum iron, total iron‐binding capacity, transferrin saturation or erythrocyte proto‐porphyrin did not differ significantly between the two groups throughout the study. After 16 weeks of therapy, the mean increase in hemoglobin iron was similar in both groups (p = 0.2). Estimates of net changes in total body iron suggested that the overall bioavailability of carbonyl iron was high, about 70% that of ferrous sulfate.